Ionis Pharmaceuticals, Inc. (IONS) Price Target Lowered to $52.00 at Barclays PLC

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) had its target price decreased by Barclays PLC from $55.00 to $52.00 in a research report issued on Thursday. The firm currently has an “equal weight” rating on the stock. Barclays PLC’s price objective indicates a potential downside of 3.49% from the company’s current price.

Other equities research analysts have also issued reports about the stock. Needham & Company LLC reiterated a “buy” rating and issued a $64.00 price target on shares of Ionis Pharmaceuticals in a research note on Wednesday, July 26th. Zacks Investment Research upgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $59.00 price target on the stock in a research note on Monday, July 31st. BMO Capital Markets reiterated a “buy” rating and issued a $59.00 price target on shares of Ionis Pharmaceuticals in a research note on Friday, June 2nd. Laidlaw reiterated a “buy” rating and issued a $65.00 price target on shares of Ionis Pharmaceuticals in a research note on Monday, August 14th. Finally, TheStreet upgraded shares of Ionis Pharmaceuticals from a “d+” rating to a “c-” rating in a research note on Wednesday, July 5th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $49.11.

Ionis Pharmaceuticals (IONS) traded down 2.9323% during trading on Thursday, hitting $52.3001. 1,095,418 shares of the stock were exchanged. The firm has a market capitalization of $6.50 billion, a PE ratio of 251.4428 and a beta of 3.13. The stock has a 50 day moving average price of $51.73 and a 200-day moving average price of $48.15. Ionis Pharmaceuticals has a 12-month low of $24.58 and a 12-month high of $60.01.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its quarterly earnings data on Tuesday, August 8th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.03). Ionis Pharmaceuticals had a return on equity of 15.52% and a net margin of 5.25%. The company had revenue of $104.15 million for the quarter, compared to analyst estimates of $93.29 million. During the same quarter in the previous year, the business earned ($0.47) earnings per share. The company’s revenue was up 170.7% on a year-over-year basis. On average, equities research analysts anticipate that Ionis Pharmaceuticals will post ($0.17) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Ionis Pharmaceuticals, Inc. (IONS) Price Target Lowered to $52.00 at Barclays PLC” was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at https://sportsperspectives.com/2017/09/21/ionis-pharmaceuticals-inc-ions-price-target-lowered-to-52-00-at-barclays-plc.html.

In other news, major shareholder Ionis Pharmaceuticals Inc bought 3,125,000 shares of the company’s stock in a transaction dated Wednesday, July 19th. The stock was bought at an average cost of $8.00 per share, for a total transaction of $25,000,000.00. Following the transaction, the insider now owns 28,884,540 shares of the company’s stock, valued at $231,076,320. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Patrick R. O’neil sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $55.00, for a total transaction of $55,000.00. Following the completion of the transaction, the senior vice president now owns 10,633 shares of the company’s stock, valued at $584,815. The disclosure for this sale can be found here. Insiders sold a total of 55,309 shares of company stock valued at $2,997,692 in the last three months. Insiders own 1.86% of the company’s stock.

Large investors have recently modified their holdings of the company. Parallel Advisors LLC raised its position in shares of Ionis Pharmaceuticals by 62.8% in the 2nd quarter. Parallel Advisors LLC now owns 2,073 shares of the company’s stock valued at $109,000 after buying an additional 800 shares in the last quarter. Hanseatic Management Services Inc. raised its position in shares of Ionis Pharmaceuticals by 1.2% in the 2nd quarter. Hanseatic Management Services Inc. now owns 3,481 shares of the company’s stock valued at $177,000 after buying an additional 41 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Ionis Pharmaceuticals by 9.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,744 shares of the company’s stock valued at $190,000 after buying an additional 311 shares in the last quarter. WFG Advisors LP raised its position in shares of Ionis Pharmaceuticals by 77.2% in the 2nd quarter. WFG Advisors LP now owns 3,800 shares of the company’s stock valued at $193,000 after buying an additional 1,655 shares in the last quarter. Finally, Westpac Banking Corp acquired a new position in shares of Ionis Pharmaceuticals in the 1st quarter valued at approximately $171,000. Institutional investors own 89.24% of the company’s stock.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Analyst Recommendations for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply